SCHEMBL1482352

SCHEMBL1482352

N#Cc1ccc(CCc2cc(Cl)ccc2-c2nc3ccccc3n2CC2CCCCC2)cc1

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 2/20 0.43
DRD2 P14416 1/20 0.43
TBXA2R P21731 1/20 0.43
KCNH2 Q12809 5/20 0.42
CTSL P07711 1/20 0.41
CTSS P25774 1/20 0.41
CTSK P43235 1/20 0.41
CNR2 P34972 2/20 0.41
PRKACA P17612 1/20 0.39
RPS6KB1 P23443 1/20 0.39
GSK3B P49841 1/20 0.39
ROCK1 Q13464 1/20 0.39
NPSR1 Q6W5P4 2/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1482351 0.89 KCNH2 (0.44) KCNH2CNR2PRKACARPS6KB1GSK3B
SCHEMBL1482886 0.88 NR1H4 (0.46) ALOX5KCNH2CTSLCTSSCTSK
SCHEMBL1482726 0.85 PTGER4 (0.47) ALOX5DRD2TBXA2R
SCHEMBL1483068 0.84 ALOX5 (0.44) ALOX5DRD2TBXA2RKCNH2CTSL
SCHEMBL1482796 0.82 ALOX5 (0.43) ALOX5DRD2KCNH2PRKACARPS6KB1
SCHEMBL1577111 0.80 KCNH2 (0.44) KCNH2CNR2NPSR1
SCHEMBL1484292 0.80 KCNH2 (0.42) DRD2TBXA2RKCNH2PRKACARPS6KB1
SCHEMBL1482732 0.80 CNR2 (0.42) ALOX5KCNH2CNR2NPSR1
SCHEMBL1577841 0.80 PTGER4 (0.44) ALOX5PRKACARPS6KB1GSK3BROCK1
SCHEMBL1482750 0.79 KCNH2 (0.41) DRD2TBXA2RKCNH2PRKACARPS6KB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8309581-B2 Benzimidazole derivatives HOFFMANN-LA ROCHE INC. (US) 2012-11-13 US disclosed
EP-2483247-A1 NEW BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS FXR AGONISTS F. Hoffmann-La Roche AG (CH) 2012-08-08 EP disclosed
WO-2011039130-A1 NEW BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS FXR AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2011-04-07 WO disclosed
US-20110077273-A1 NEW BENZIMIDAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2011-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110077273-A1 NEW BENZIMIDAZOLE DERIVATIVES BRI3BP, CYP3A4, RB1 ALOX5 3919/4885DRD2 1464/4885TBXA2R 92/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.